Thus, measuring EGFR and HER2 levels in patients with NSCLC has been evaluated to predict the anti-cancer activity of gefitinib (a TKI) due to increased HER2, in patients with EGFR-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.